KRKA dd
- Country
- 🇸🇮Slovenia
- Ownership
- Public
- Established
- 1954-04-23
- Employees
- 11.7K
- Market Cap
- -
- Website
- http://www.krka.biz
Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Efficacy of Pregabalin and Duloxetine in Patients With PDPN: the Effect of Pain on Cognitive Function, Sleep and Quality of Life
- Conditions
- Painful Diabetic Peripheral Neuropathy
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- KRKA
- Target Recruit Count
- 254
- Registration Number
- NCT04246619
- Locations
- 🇭🇷
Opća bolnica Karlovac, Karlovac, Croatia
🇭🇷Clinical Medical Center Osijek, Osijek, Croatia
🇭🇷KB Merkur, Sveučilišna klinika Vuk Vrhovac, Zagreb, Croatia
Management of Newly Diagnosed and Uncontrolled Hypertension With Fixed-Dose Combination of Perindopril/Amlodipine and Perindopril/Indapamide/Amlodipine
- Conditions
- Hypertension
- Interventions
- Drug: Co-Amlessa®Drug: Amlessa®
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- KRKA
- Target Recruit Count
- 471
- Registration Number
- NCT03738761
- Locations
- 🇦🇲
Unimed medical center, Abovyan, Armenia
🇦🇲Center of Preventive Cardiology, Yerevan, Armenia
🇭🇷Thalassotherapia Opatija, Specijalna bolnica za medicinsku rehabilitaciju, bolesti srca, pluća i reumatizma, Klinika za liječenje, rehabilitaciju i prevenciju bolesti srca i krvnih žila, Opatija, Croatia
Prevention of Ischemic Events in Patients With Peripheral Arterial Disease
- Conditions
- Peripheral Arterial Disease
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2015-11-17
- Lead Sponsor
- KRKA
- Target Recruit Count
- 1455
- Registration Number
- NCT00761969
- Locations
- 🇸🇮
Department of Vascular Diseases, University of Ljubljana Medical Center, Ljubljana, Slovenia
News
German Federal Patent Court Revokes Key Xarelto Patent, Opening Door for Generic Competition
The German Federal Patent Court revoked Bayer's crucial Xarelto patent EP 1 845 961 due to lack of inventive step, contradicting its earlier 2024 opinion that assumed the patent's validity.